ING FX Talking
KRS Capital LLC Investor Deck
The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
The Art of the Squeeze Play Presented by: Philip B. Erlanger, CMT Phil Erlanger Research Co., Inc February, 2009 © 2009 Phil Erlanger Research Co., Inc.
Strategies in Volatile Times – MineAfrica James E. Kofman – Vice Chairman, UBS Securities Canada January 13, 2009.
3-Year KTB Futures Success Factors & Outlook 2003 Taipei Interest Rate Futures Conference November 20-21, 2003 Jungho Kang, Ph.D Korea Futures Exchange.
3-Year KTB Futures Success Factors & Outlook
